1. The autonomic nervous system (ANS) governs which of the following functional domains, and why does this scope directly determine which organ systems are targeted by autonomic drugs?

• A) The ANS governs voluntary control of skeletal muscle through alpha motor neurons in the anterior horn of the spinal cord — autonomic pharmacology therefore targets the neuromuscular junction as its principal site of drug action, where acetylcholine activates nicotinic receptors on skeletal muscle fibers
• B) The ANS governs the conscious perception of pain and temperature through dorsal column and spinothalamic pathways — autonomic drugs act primarily by altering sensory thresholds at spinal cord relay nuclei
• C) The ANS governs involuntary control of smooth muscle, cardiac muscle, and glandular secretion throughout the body — this functional scope means that autonomic drugs achieve their therapeutic effects by targeting the receptors, neurotransmitters, and signal transduction pathways that regulate these visceral functions, including blood vessel tone, heart rate, bronchial caliber, gastrointestinal motility, bladder function, and exocrine gland secretion
• D) The ANS governs transmission of proprioceptive signals from joints and tendons through spinocerebellar tracts — autonomic pharmacology therefore targets the cerebellum and basal ganglia as its primary sites of drug action
• E) The ANS governs integration of somatic and visceral sensory information at the thalamus — autonomic drugs act by modulating thalamic relay nuclei to selectively filter visceral pain signals

2. The sympathetic division of the ANS is designated the thoracolumbar outflow. Which of the following correctly identifies where sympathetic preganglionic neurons originate and why this anatomical location gives rise to that designation?

• A) Sympathetic preganglionic neurons originate in the intermediolateral cell column (IML) of the spinal cord, spanning thoracic segment T1 through upper lumbar segments L2–L3 — this anatomical origin in thoracic and upper lumbar cord segments is the direct basis for the designation thoracolumbar outflow; preganglionic axons exit via ventral roots and travel through the white rami communicantes to reach the sympathetic chain
• B) Sympathetic preganglionic neurons originate in the dorsal horn of the spinal cord spanning S2 through S4 — this sacral origin gives rise to the craniosacral designation, and the term thoracolumbar is used informally to describe the distribution of postganglionic fibers rather than the location of preganglionic cell bodies
• C) Sympathetic preganglionic neurons originate in four cranial nerve nuclei in the brainstem — the Edinger-Westphal nucleus, the superior and inferior salivatory nuclei, and the dorsal motor nucleus of the vagus — making the sympathetic division a cranial outflow
• D) Sympathetic preganglionic neurons originate in Clarke's nucleus spanning T1 through L2 — Clarke's nucleus serves as the integration center for both sympathetic preganglionic outflow and spinocerebellar tract neurons
• E) Sympathetic preganglionic neurons originate in the anterior horn of the spinal cord at all levels from C1 through S5 — the thoracolumbar designation refers only to the segments where preganglionic output is greatest in magnitude, not to the exclusive anatomical origin

3. The parasympathetic division is designated the craniosacral outflow. Which cranial nerve carries the largest proportion of total parasympathetic preganglionic output, and which organ systems does it reach?

• A) The trigeminal nerve (CN V) carries the largest proportion of parasympathetic preganglionic output — it distributes postganglionic parasympathetic fibers from the pterygopalatine, submandibular, and otic ganglia to the lacrimal gland, salivary glands, and nasal mucosa
• B) The facial nerve (CN VII) carries the largest proportion of parasympathetic preganglionic output — its preganglionic fibers originate in the superior and inferior salivatory nuclei and travel to the pterygopalatine and submandibular ganglia
• C) The glossopharyngeal nerve (CN IX) carries approximately 75% of total parasympathetic preganglionic output — it innervates the heart, lungs, and the entire gastrointestinal tract through the otic ganglion
• D) The oculomotor nerve (CN III) carries the largest proportion of parasympathetic preganglionic output — its extensive peripheral distribution through the ciliary ganglion accounts for the majority of visceral parasympathetic control
• E) The vagus nerve (CN X) carries approximately 75% of total parasympathetic preganglionic output — its preganglionic fibers originate from the dorsal motor nucleus and nucleus ambiguus in the medulla and travel to terminal ganglia embedded within the thoracic and abdominal viscera, innervating the heart, lungs, esophagus, stomach, small intestine, and proximal large intestine as far as the splenic flexure

4. The autonomic nervous system uses a two-neuron pathway from the CNS to the effector organ, unlike the somatic motor system which uses a single neuron. Which of the following correctly describes the two neurons and the synapse between them?

• A) The first neuron (preganglionic) releases norepinephrine onto nicotinic NN receptors on the postganglionic cell body in sympathetic ganglia; the second neuron (postganglionic) releases acetylcholine at parasympathetic effector organs and norepinephrine at sympathetic effector organs
• B) The first neuron (preganglionic) has its cell body in the CNS, travels to an autonomic ganglion, and releases acetylcholine onto nicotinic NN receptors on the postganglionic cell body — this is true for both sympathetic and parasympathetic divisions; the second neuron (postganglionic) travels from the ganglion to the effector organ, where sympathetic postganglionic fibers release norepinephrine and parasympathetic postganglionic fibers release acetylcholine
• C) The first neuron (preganglionic) has its cell body in the autonomic ganglion and travels to the spinal cord to receive input from descending pathways; the second neuron (postganglionic) travels from the spinal cord to the effector organ and releases acetylcholine at all effector synapses regardless of division
• D) The first neuron releases acetylcholine in the sympathetic division and norepinephrine in the parasympathetic division — this chemical difference at the ganglionic synapse is what distinguishes the two divisions at the molecular level
• E) The two-neuron architecture applies only to the parasympathetic division — the sympathetic division uses a single neuron from the spinal cord directly to the effector organ, with norepinephrine released at the neuroeffector junction

5. The enteric nervous system (ENS) is sometimes called the "second brain" because it can sustain coordinated gastrointestinal function independently of the central ANS. Which of the following correctly identifies the two principal plexuses of the ENS and their primary functional roles?

• A) The solar plexus and the hypogastric plexus — the solar plexus governs upper GI motility and the hypogastric plexus governs lower GI and urogenital function; together they constitute the ENS
• B) The celiac plexus and the mesenteric plexus — these two prevertebral sympathetic ganglia constitute the ENS and distribute sympathetic postganglionic fibers to all abdominal organs
• C) The dorsal vagal complex and the nucleus tractus solitarius — these brainstem nuclei constitute the central component of the ENS and coordinate GI function; enteric function is entirely dependent on this brainstem circuit
• D) The myenteric (Auerbach's) plexus and the submucosal (Meissner's) plexus — the myenteric plexus lies between the longitudinal and circular muscle layers and governs primarily gastrointestinal motility and peristaltic coordination; the submucosal plexus lies in the submucosa and governs primarily local blood flow, epithelial secretion, and absorption; together they contain an estimated 200–600 million neurons and can sustain coordinated GI function in the complete absence of extrinsic ANS input
• E) The myenteric plexus lies in the submucosa and governs secretion, while the submucosal plexus lies between the muscle layers and governs motility — the reversed anatomical positions relative to their functions explains why surgical disruption of the outer bowel wall selectively impairs secretion while preserving motility

6. Ganglionic blockers interrupt transmission at a specific anatomical site in the ANS. Which of the following correctly identifies that site and explains why ganglionic blockade affects both sympathetic and parasympathetic divisions simultaneously?

• A) Ganglionic blockers act at the nicotinic NN receptor on the postganglionic neuron cell body within the autonomic ganglion — because both sympathetic and parasympathetic preganglionic fibers release acetylcholine acting on NN receptors at the ganglionic synapse, blockade of these receptors interrupts transmission in both divisions simultaneously; trimethaphan and hexamethonium are prototypical ganglionic blockers
• B) Ganglionic blockers act at the postganglionic adrenergic nerve terminal, preventing norepinephrine release through voltage-gated calcium channel blockade — because norepinephrine is released by sympathetic fibers only, ganglionic blockade is purely sympatholytic
• C) Ganglionic blockers act at the muscarinic M2 receptor on the postganglionic neuron, blocking the slow excitatory postsynaptic potential that sustains postganglionic firing — because M2 receptors are present in sympathetic ganglia only, ganglionic blockers produce a pure sympatholytic profile
• D) Ganglionic blockers act at the nicotinic NM receptor at the neuromuscular junction, producing non-depolarizing competitive blockade of skeletal muscle — they are classified as ganglionic blockers because the neuromuscular junction is anatomically equivalent to an autonomic ganglion in developmental terms
• E) Ganglionic blockers act at alpha-2 adrenergic receptors on the preganglionic neuron terminal within the ganglion, reducing acetylcholine release through presynaptic inhibition — because alpha-2 receptors are present in both sympathetic and parasympathetic ganglia, blockade produces combined effects

7. A 55-year-old man presents with right-sided ptosis (drooping of the upper eyelid), right pupil measuring 2 mm compared with a left pupil of 5 mm, and absence of sweating over the right face and neck. Chest imaging reveals a right apical lung mass. Which of the following most accurately identifies the anatomical pathway disrupted in this patient?

• A) The apical lung mass is compressing the right vagus nerve (CN X) as it descends into the thorax, disrupting parasympathetic tone to the right eye and face — loss of M3 muscarinic activation of the iris sphincter produces mydriasis, and loss of parasympathetic secretomotor fibers produces anhidrosis over the ipsilateral face
• B) The apical lung mass is compressing the right phrenic nerve, which provides the primary autonomic innervation to the face and orbit through a cervical anastomosis with the superior cervical ganglion
• C) The apical lung mass is disrupting the second-order sympathetic neuron as it travels from the T1–T2 intermediolateral cell column over the right pulmonary apex en route to the superior cervical ganglion — interruption of this pathway denervates the superior tarsal muscle (producing ptosis), the iris dilator pupillae (producing miosis — pupil constriction), and ipsilateral facial sudomotor fibers (producing anhidrosis), constituting Horner syndrome
• D) The apical lung mass has invaded the right superior cervical ganglion directly, disrupting third-order sympathetic neurons — topical cocaine 4% instilled in both eyes would fail to dilate the right (affected) pupil while the left pupil dilates normally, because cocaine blocks norepinephrine reuptake and requires intact postganglionic terminals to accumulate norepinephrine at the dilator muscle; a preganglionic (second-order) lesion such as the one in this patient would also fail the cocaine test, so cocaine cannot distinguish second-order from third-order Horner syndrome
• E) The apical lung mass is compressing the right brachial plexus at C8–T1, producing lower trunk plexopathy — the ptosis, miosis, and anhidrosis are somatic motor and sensory deficits from lower trunk involvement rather than autonomic deficits

8. The adrenal medulla is described as a modified sympathetic ganglion. Which of the following correctly explains what this designation means and why it has pharmacological significance?

• A) The adrenal medulla receives postganglionic noradrenergic innervation from the celiac ganglion and responds to norepinephrine by releasing epinephrine through a beta-1 receptor-mediated mechanism — the designation reflects the adrenal medulla's functional equivalence to a sympathetic effector organ
• B) The adrenal medulla is innervated by somatic motor fibers from the phrenic nerve that trigger catecholamine secretion during inspiratory effort — the ganglionic designation reflects the medulla's shared embryological origin with the diaphragm
• C) The adrenal medulla contains parasympathetic postganglionic neurons derived from the vagal neural crest that synthesize primarily acetylcholine and vasoactive intestinal peptide
• D) The adrenal medulla functions as a relay ganglion for the sympathetic chain, receiving preganglionic input from T5–T9 and distributing postganglionic noradrenergic fibers to the kidney, adrenal cortex, and gonads — epinephrine is not produced in the medulla but in the adrenal cortex
• E) The adrenal medulla contains chromaffin cells that are embryologically derived from the same neural crest lineage as sympathetic postganglionic neurons but have lost their axons during development and become secretory cells instead — they receive direct preganglionic cholinergic innervation from the splanchnic nerves (T5–T9) without an interposed postganglionic neuron; acetylcholine activates nicotinic NN receptors on chromaffin cells, triggering release of approximately 80% epinephrine and 20% norepinephrine directly into the systemic circulation as hormones

9. Eccrine sweat glands receive sympathetic innervation, yet the postganglionic fibers supplying them release acetylcholine rather than norepinephrine. Which of the following correctly identifies the clinical consequence of this pharmacological exception?

• A) Because eccrine sweat glands are innervated by sympathetic cholinergic fibers releasing acetylcholine at muscarinic M3 receptors, a drug that selectively blocks muscarinic receptors (such as atropine) will suppress sweating despite having no direct effect on noradrenergic sympathetic pathways — anhidrosis (absence of sweating) from atropine is therefore a muscarinic, not an adrenergic, side effect
• B) Because eccrine sweat glands receive cholinergic sympathetic innervation, beta-adrenergic blockers such as propranolol produce anhidrosis as their primary autonomic side effect — propranolol's beta-2 blockade of the cholinergic sympathetic fibers supplying sweat glands removes the tonic sweating signal
• C) The cholinergic innervation of sweat glands means that alpha-1 adrenergic agonists such as phenylephrine stimulate sweating by cross-activating muscarinic receptors at the sweat gland — this cross-receptor activation explains the diaphoresis (profuse sweating) associated with sympathomimetic drug administration
• D) Because sweat glands are the only organ supplied by sympathetic cholinergic fibers, selective disorders of this pathway produce isolated anhidrosis with preservation of all other sympathetic functions — making isolated generalized anhidrosis a diagnostically informative finding that specifically implicates the sympathetic cholinergic pathway
• E) The cholinergic innervation of sweat glands is a vestigial feature with no clinical relevance — in practice, sweating is controlled by circulating epinephrine from the adrenal medulla acting on alpha-1 receptors at the eccrine secretory coil

10. Visceral referred pain is perceived as arising from a remote somatic location despite originating from a visceral organ. Which of the following correctly explains the neuroanatomical basis for this phenomenon and gives a clinically relevant example?

• A) Visceral pain afferents travel with parasympathetic nerves to the nucleus tractus solitarius in the brainstem, which projects diffusely to somatosensory cortex — the imprecision of cortical representation for visceral input produces the mislocalisation of visceral pain to distant body regions
• B) Visceral pain afferents travel with sympathetic nerves through the dorsal roots and converge on the same dorsal horn neurons as somatic cutaneous afferents from anatomically distant body regions sharing the same spinal segments — the CNS cannot distinguish the source of activation at these shared dorsal horn neurons and attributes the pain to the more commonly stimulated somatic region; cardiac ischemia (T1–T5 visceral afferents) is therefore referred to the chest, left arm, and jaw whose cutaneous afferents enter at the same spinal levels
• C) Visceral afferents travel with sympathetic nerves but cross the midline in the spinal cord before ascending in the spinothalamic tract — this midline crossing explains why visceral pain is always bilateral and never lateralizing
• D) Visceral referred pain results from antidromic conduction in somatic afferents triggered by visceral afferent activity at the dorsal root ganglion — the antidromic signal travels peripherally along the somatic afferent and releases substance P in the dermatomal territory
• E) Visceral pain afferents travel with sympathetic nerves and cross the midline at the level of the dorsal column nuclei — because both sides of the body share the same dorsal column representation for visceral pain, cardiac ischemia always produces bilateral arm pain with equal intensity on both sides

11. Clonidine is a centrally acting antihypertensive that reduces sympathetic outflow by acting on alpha-2 adrenergic receptors in brainstem nuclei. A patient on long-term clonidine stops taking it abruptly. Which of the following best predicts the consequence and its mechanism?

• A) Abrupt clonidine discontinuation produces rebound hypertension — chronic central alpha-2 agonism suppresses tonic sympathetic preganglionic outflow, leading to compensatory upregulation of peripheral alpha-1 receptors and increased presynaptic norepinephrine synthesis; when clonidine is withdrawn, the unoppressed central sympathetic drive activates these upregulated, sensitized peripheral receptors, producing a catecholamine surge and hypertensive rebound that may exceed pre-treatment blood pressure levels; clonidine must always be tapered gradually rather than stopped abruptly
• B) Abrupt clonidine discontinuation produces rebound bradycardia — chronic suppression of the RVLM reduces heart rate below the intrinsic SA node rate; withdrawal removes this suppression but the SA node requires 24–48 hours to recover its intrinsic pacemaker function
• C) Abrupt clonidine discontinuation produces no clinically significant effect — clonidine's antihypertensive effect is entirely pharmacokinetic rather than pharmacodynamic, so cessation simply allows blood pressure to return gradually to baseline
• D) Abrupt clonidine discontinuation produces acute parasympathetic dominance — chronic alpha-2 agonism in the brainstem suppresses both sympathetic and parasympathetic outflow simultaneously; withdrawal releases both divisions together, but the parasympathetic system recovers faster, producing transient bradycardia and excessive salivation
• E) Abrupt clonidine discontinuation produces acute sedation — clonidine's central alpha-2 agonism in the locus coeruleus maintains wakefulness; withdrawal of this agonist signal produces a prolonged sedative state lasting 48–72 hours

12. The rostral ventrolateral medulla (RVLM) is the principal sympathetic vasomotor center in the brainstem, providing tonic excitatory drive to sympathetic preganglionic neurons in the IML. Which of the following correctly identifies where centrally acting sympatholytic drugs exert their effect, and names the two major drugs in this class?

• A) Centrally acting sympatholytic drugs act at alpha-2 adrenergic receptors and imidazoline I1 receptors in the NTS and RVLM circuit, reducing tonic excitatory output to IML sympathetic preganglionic neurons and thereby lowering peripheral vascular resistance and heart rate — clonidine is a direct alpha-2 agonist at these sites; methyldopa is converted to alpha-methylnorepinephrine in CNS adrenergic neurons, which then acts as an alpha-2 agonist at the same brainstem sites; because they reduce central sympathetic drive globally, they produce broader autonomic effects than peripheral antihypertensives, including sedation and dry mouth
• B) Centrally acting sympatholytic drugs act at nicotinic NN receptors in the paravertebral sympathetic ganglia, reducing ganglionic transmission — clonidine and methyldopa are prototypical ganglionic-level agents
• C) Centrally acting sympatholytic drugs act at the sympathetic postganglionic terminal in peripheral tissues, blocking norepinephrine release through a presynaptic alpha-2 mechanism — reserpine and guanethidine are the prototypical agents
• D) Centrally acting sympatholytic drugs act at GABA-B receptors in the RVLM, hyperpolarizing vasomotor neurons — baclofen and gabapentin are the prototypical agents
• E) Centrally acting sympatholytic drugs act at muscarinic M1 receptors in the hypothalamic paraventricular nucleus, reducing CRH release and thereby lowering sympathetic tone through a neuroendocrine mechanism — atropine and scopolamine are the prototypical agents

13. A patient is given trimethaphan (a ganglionic blocker) intravenously for acute severe hypertension. The expected heart rate response is tachycardia, not bradycardia. Which of the following correctly explains why ganglionic blockade produces tachycardia rather than bradycardia?

• A) Trimethaphan produces tachycardia by directly activating beta-1 adrenergic receptors on the SA node through a partial agonist mechanism at the nicotinic receptor — the partial agonist activity releases the intrinsic SA node firing rate from ganglionic inhibition
• B) Trimethaphan produces tachycardia because ganglionic blockade removes the dominant resting vagal (parasympathetic) tone from the SA node — at rest, the heart rate is held below the intrinsic SA node rate of approximately 100–110 bpm by ongoing vagal M2-mediated inhibition; when ganglionic blockade eliminates this vagal input, the SA node fires at or near its intrinsic rate, producing tachycardia
• C) Trimethaphan produces tachycardia through a reflex baroreceptor mechanism — ganglionic blockade reduces peripheral vascular resistance, lowering blood pressure; the fall in blood pressure activates baroreceptors that reflexly increase sympathetic outflow directly to the SA node, bypassing the blocked ganglia
• D) Trimethaphan produces tachycardia because ganglionic blockade removes sympathetic tone from the SA node — without sympathetic drive, the SA node fires at its intrinsic rate of approximately 100 bpm, which is higher than the normal resting heart rate of 60–80 bpm that reflects dominant parasympathetic tone suppression
• E) Trimethaphan produces bradycardia rather than tachycardia — the expected response to ganglionic blockade is slowing of the heart rate because the sympathetic division provides the dominant resting chronotropic drive to the SA node, and removing it unmasks the slower intrinsic SA node pacemaker rate of approximately 40 bpm

14. Which of the following correctly describes the ganglionic nicotinic receptor (NN) and explains why it is pharmacologically distinguishable from the neuromuscular junction nicotinic receptor (NM)?

• A) The NN and NM receptors have identical subunit compositions but differ in their anatomical location — NN receptors are located at autonomic ganglia and NM receptors at the neuromuscular junction; the clinical selectivity of ganglionic blockers and neuromuscular blockers reflects pharmacokinetic differences in drug distribution to each site rather than any molecular pharmacodynamic distinction
• B) The NN receptor is a pentameric ligand-gated ion channel identical in subunit composition to the NM receptor — both contain alpha1, beta1, delta, and epsilon subunits; the pharmacological difference between ganglionic blockers and neuromuscular blockers reflects differences in drug molecular size rather than receptor subunit differences
• C) The NN and NM receptors are pharmacologically identical — both are pentameric ligand-gated sodium channels with the same subunit composition; the apparent clinical selectivity of ganglionic blockers and neuromuscular blockers reflects pharmacokinetic rather than pharmacodynamic differences
• D) The NN receptor is a pentameric ligand-gated ion channel composed predominantly of alpha3 and beta4 subunits — its different subunit composition from the NM receptor (which contains alpha1, beta1, delta, and epsilon/gamma subunits) creates a different binding site geometry; this subunit difference is the pharmacological basis for the clinical selectivity of neuromuscular blockers (rocuronium, vecuronium) for NM receptors without ganglionic blockade, and of ganglionic blockers (hexamethonium, trimethaphan) for NN receptors without neuromuscular blockade
• E) The NN receptor is a tetrameric ionotropic glutamate receptor requiring simultaneous binding of acetylcholine and glycine for channel opening — this co-agonist requirement distinguishes it from the NM receptor which requires only acetylcholine

15. Having worked through the anatomical organization of the ANS in this module, which of the following statements most accurately summarizes why understanding the two-neuron pathway and neurotransmitter pharmacology at each synapse is the essential foundation for predicting the effects of autonomic drugs?

• A) The two-neuron architecture is clinically relevant only for ganglionic blockers — all other autonomic drugs act at the postganglionic-to-effector synapse where the two divisions differ in neurotransmitter; understanding the preganglionic synapse adds no additional predictive power for the effects of drugs acting beyond the ganglion
• B) The two-neuron architecture and neurotransmitter pharmacology at each synapse allow a clinician to predict, from first principles, where any given autonomic drug acts, which division(s) it affects, and what the full pattern of organ effects will be — a drug blocking muscarinic receptors will produce effects predictable from the loss of parasympathetic postganglionic output to all M-receptor-bearing organs simultaneously; a drug blocking ganglionic NN receptors will lose both divisions' output simultaneously; a drug that releases norepinephrine will activate all adrenergic receptors throughout the body in proportion to their distribution; this framework converts autonomic pharmacology from a list of drug effects to be memorized into a set of logical consequences derivable from anatomy and receptor pharmacology
• C) The two-neuron pathway is important primarily as a safety feature — having a synapse between the CNS and the effector organ ensures that autonomic reflexes cannot be triggered accidentally by CNS signals; the pharmacological consequence is that all autonomic drugs must cross the ganglionic synapse to reach their target
• D) The neurotransmitter pharmacology at each synapse is relevant for understanding drug mechanisms but does not help predict side effects — side effects of autonomic drugs arise from off-target receptor binding that is independent of the two-neuron architecture and must be determined empirically for each drug individually
• E) The two-neuron pathway is clinically relevant mainly for understanding why autonomic drugs have slow onset — the additional synapse introduces a pharmacokinetic delay at the ganglion that slows the time to effector organ effect; removing this delay is the primary therapeutic advantage of postganglionic agents over preganglionic ones